<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
NTLA
Intellia Therapeutics
$
()


  • Intellia Therapeutics announces first patient dosed in Phase 3 MAGNITUDE study

    3/18/2024 - 07:38am
  • Intellia Therapeutics just downgraded at Goldman Sachs, here's why

    2/23/2024 - 09:18am
  • Intellia Therapeutics price target lowered by $14 at Guggenheim, here's why

    2/23/2024 - 08:47am
  • Intellia Therapeutics price target raised by $1 at Canaccord, here's why

    2/23/2024 - 07:22am
  • Intellia Therapeutics reports Q4 EPS ($1.46), consensus ($1.45)

    2/22/2024 - 07:35am
  • Intellia Therapeutics price target lowered by $14 at Baird, here's why

    2/16/2024 - 07:14am
  • Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF

    2/15/2024 - 07:43am
  • Intellia Therapeutics, ReCode Therapeutics announce collaboration

    2/15/2024 - 07:36am
  • Intellia Therapeutics initiated with neutral view at Wolfe Research, here's why

    2/14/2024 - 19:23pm
  • Intellia Therapeutics initiated with neutral view at Wolfe Research

    2/14/2024 - 16:16pm
  • Cathie Wood's ARK Investment bought 131K shares of Intellia Therapeutics today

    2/5/2024 - 20:04pm
  • Intellia Therapeutics announces publication of NTLA-2002 data in NEJM

    1/31/2024 - 17:02pm
  • Cantor Fitzgerald biotech analysts hold an analyst/industry conference call

    1/30/2024 - 13:15pm
  • Cantor Fitzgerald biotech analysts hold an analyst/industry conference call

    1/30/2024 - 10:55am
  • Intellia Therapeutics price target lowered by $13 at Stifel, here's why

    1/8/2024 - 09:55am
dynamic_feed Breaking News